Pterygium Surgery 

The conjunctiva is the clear, thin membrane that covers the white of the eye. Years of UV light, wind, and dust can thicken small clusters of that tissue. Over time, this recruits new blood vessels and slowly pushes the growth onto the cornea. Once the growth crosses onto the cornea, it becomes a pterygium, and it can distort the corneal curvature with surprising precision. The long-established surgical treatment is conjunctival autograft. During this procedure, Dr. Bradley Barnett removes the abnormal tissue and covers the exposed area with a small patch of the patient’s own healthy conjunctiva. 

Decades of peer-reviewed evidence support this approach, and in real-world review data, conjunctival autograft recurrence rates cluster around 5 to 9 percent, depending on technique and fixation method. The technique works, and the science is well established. Suture-based autograft is no longer the only durable option, and at California LASIK & Eye in Sacramento, we do not default to yesterday's approach when a better one is available. 

Dr. Barnett performs pterygium excision paired with Biovance 3L Ocular, a triple-layer decellularized human amniotic basement membrane graft supplied through Defeye for patients in Sacramento, Roseville, Folsom, Elk Grove, and Davis. During the procedure, the membrane is placed over the surgical bed without sutures or fibrin glue, using a technique documented in peer-reviewed ophthalmology literature. 

What Is a Pterygium (Surfer's Eye)? 

A pterygium is a benign, wedge-shaped growth of conjunctival tissue that extends onto the cornea, most often on the nasal side of the eye. It develops slowly, over years, in response to chronic UV light, wind, dust, and ocular surface dryness. Long-term UV exposure is the most consistent environmental risk factor identified in ophthalmic epidemiology. The nickname surfer's eye reflects the pattern seen in outdoor athletes, farmers, construction workers, and anyone who spends significant time in bright, dry, or windy environments. In the Sacramento Valley, that describes a large share of the population. 

Do I Actually Need Surgery? 

Not every pterygium requires surgery. Small, asymptomatic growths are typically monitored with UV-protective sunglasses, lubricating eye drops, and periodic exams. The American Academy of Ophthalmology recommends surgical removal when a pterygium threatens vision, causes persistent irritation, or affects appearance significantly. At California LASIK & Eye, Dr. Barnett only recommends surgery when the clinical picture supports it. We recommend only what is right for each patient, even if that is watchful waiting. 

Why Biovance 3L Changes the Recurrence Conversation 

Recurrence is the single most important outcome in pterygium surgery. Historic bare-sclera excision techniques carried recurrence rates as high as 40 percent or more. Modern conjunctival autograft lowers that to roughly 5 to 9 percent, and fibrin-glue fixation trends toward the low end of that range, closer to 4 to 6 percent in long-term follow-up data. Biovance 3L Ocular is a triple-layer, decellularized human amniotic basement membrane. The decellularization process removes pro-inflammatory chorion and residual donor cellular debris while preserving extracellular matrix proteins such as collagen, laminin, and fibronectin. In a 2026 retrospective review published in Ophthalmology and Therapy, a glueless, sutureless pterygium excision technique using Biovance 3L Ocular reported no recurrences and no pyogenic granuloma, dellen, or infection events in in the study cohort, an encouraging early-stage finding, though longer-term, larger studies are still accumulating. For patients, that translates into three practical advantages: shorter surgical time, no sutures irritating the eye during healing, and a graft designed to lower the risk of the pterygium returning. 

Why Patients Choose Dr. Bradley Barnett 

Dr. Bradley Barnett, MD, PhD, is the founder and medical director of California LASIK & Eye. He completed his MD-PhD at Johns Hopkins School of Medicine, his ophthalmology residency at the Johns Hopkins Wilmer Eye Institute, and his fellowship in cornea and refractive surgery at UCSD Shiley Eye Institute. He served as an assistant professor of cornea and refractive surgery at Duke University before founding California LASIK & Eye in 2021. With seven years of post-fellowship surgical experience, Dr. Barnett has performed more than 25,900 procedures, has published 38 peer-reviewed papers including work in Nature Medicine and Science, and holds 5 granted patents in medical device innovation. He is a 2025 Best Cataract Surgeons in America honoree and was the first ophthalmologist in Greater Sacramento to offer several advanced corneal analysis and refractive technologies. 

For pterygium patients, three things matter: his cornea fellowship training, his depth of experience with ocular surface disease, and his willingness to say no when surgery is not the right answer. When Dr. Barnett does recommend surgery, patients get a technique built around the latest peer-reviewed evidence rather than the default of a decade ago.